ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 823

A Phase 2 Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness in Subjects with Systemic Sclerosis with Interstitial Lung Disease

Vivien Hsu1, Christopher P.Denton2, Robyn T. Domsic3, Daniel E. Furst4, Maureen Rischmueller5, Marina Stanislav6, Virginia D. Steen7, Douglas Hough8, Shimon Korish9, Alyse Cooper10, Peter H. Schafer11 and Suktae Choi12, 1Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, 2Centre of Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, 3Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, 4David Geffen School of Medicine at UCLA, Los Angeles, CA, 5University of Adelaide, Adelaide, Australia, 6Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russia, 7Rheumatology, Georgetown University Medical Center, Washington, DC, 8Clinical Research, Celgene Corporation, Warren, NJ, 933 Technology Drive, Celgene Corporation, Warren, NJ, 10Immunology & Inflammation, Clinical Research, Celgene Corporation, Summit, NJ, 11Department of Translational Development, Celgene Corporation, Summit, NJ, 12Biostatistics, Celgene Corporation, Summit, NJ

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: fibrosis, interstitial lung disease, pulmonary complications, scleroderma and skin fibrosis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Session Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  Pomalidomide (POM) is an IMiD compound, structurally similar to thalidomide. POM binds to cereblon and facilitates Ikaros and Aiolos degradation, resulting in immunomodulation of myeloid and lymphocyte cell responses. POM exhibits anti-fibrotic activity in preclinical models of dermal fibrosis. To examine the effect of POM on systemic sclerosis with interstitial lung disease [SSC-ILD], the safety and efficacy of POM on forced vital capacity (FVC), modified Rodnan Skin Score (mRSS), and gastrointestinal  symptomatology as measured by the University of California, Los Angeles (UCLA) Scleroderma Clinical Trial Consortium Gastrointestinal Tract (SCTC GIT) 2.0 instrument total score compared to placebo in subjects with SSC-ILD was assessed over 52 weeks of treatment (NCT01559129).

Methods:  23 SSC-ILD adult subjects were randomized 1:1 POM:placebo (PBO) with 22 subjects dosed. Subjects were required to have a diagnosis of SSc based on the American College of Rheumatology (ACR) 1980 criteria with onset of the first non‑Raynaud’s manifestation of SSc within 7 years of screening. Diffusion lung capacity for carbon monoxide (DLco) ≥ 35% and ≤ 80% was required at screening along with abnormalities on high resolution computed tomography (HRCT) consistent with SSc lung involvement. Subjects were required to meet at least one of the following 2 pulmonary-related criteria to be eligible: (1)FVC readings ≥ 45% and < 70% at Screening and Baseline (Visit 2); or (2) FVC readings ≥ 70% and ≤ 80% at Screening and Baseline with a documented history of either or both: (a) A ≥ 5% decrease in FVC in the 24-month period prior to Baseline; (b) An HRCT fibrosis score > 20%. Subjects received either 1 mg POM capsule PO QD or placebo.

Results: The mean change from Baseline in predicted FVC% at Week 52 was -5.2 and -2.8 in the POM and PBO arms, respectively; for the mRSS at Week 52 was -2.7 and -3.7 in the POM and PBO arms, respectively; and for the UCLA SCTC GIT 2.0 instrument total score at Week 52 was 0.1 and 0.0 in the POM and PBO arms, respectively. In  both  groups  there  was  deterioration in FVC  and  improvement  in  mRSS,  and the observed changes in all three co-primary efficacy endpoints favored placebo. Overall treatment emergent adverse events (TEAEs) were comparable across both treatment arms. The most frequently reported TEAEs (in ≥ 3 subjects) in the POM arm were constipation and arthralgia. There were no deaths in the study. Severe, serious, or TEAEs leading to discontinuation in the POM arm occurred in four (40%) of the 10 subjects each. In the PBO arm, severe and serious TEAEs were each reported in one (8.3%) of the 12 subjects.

Conclusion:  In this study, POM was well tolerated with an AE profile consistent with the known safety for POM use in other diseases. The study did not meet its primary endpoints of improvement in FVC, mRSS, nor for the UCLA SCTC GIT 2.0 total score at Week 52. The study was terminated for lack of efficacy.  


Disclosure: V. Hsu, None; C. P.Denton, GSL, Celgene, Actelion, Bayer, Sanofi, 5,CSL, Behring, GSK, Actelion, 2; R. T. Domsic, Bayer Healthcare, 2,Biogen-Idec, 2; D. E. Furst, AbbVie, Actelion, Amgen, BMS, NIH, Novartis, Pfizer, Roche/Genentech, 2,AbbVie, Actelion, Amgen, BMS, Cytori, Novartis, Pfizer, Roche/Genentech, 5; M. Rischmueller, None; M. Stanislav, None; V. D. Steen, None; D. Hough, Celgene Corporation, 3,Celgene, 1; S. Korish, Celgene, 1,Celgene, 3; A. Cooper, Celgene, 1,Celgene, 3; P. H. Schafer, Celgene, 1,Celgene, 3; S. Choi, Celgene, 3,Celgene, 1.

To cite this abstract in AMA style:

Hsu V, P.Denton C, Domsic RT, Furst DE, Rischmueller M, Stanislav M, Steen VD, Hough D, Korish S, Cooper A, Schafer PH, Choi S. A Phase 2 Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness in Subjects with Systemic Sclerosis with Interstitial Lung Disease [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/a-phase-2-study-of-pomalidomide-cc-4047-to-evaluate-safety-tolerability-pharmacokinetics-pharmacodynamics-and-effectiveness-in-subjects-with-systemic-sclerosis-with-interstitial-lung-disease/. Accessed July 2, 2022.
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-phase-2-study-of-pomalidomide-cc-4047-to-evaluate-safety-tolerability-pharmacokinetics-pharmacodynamics-and-effectiveness-in-subjects-with-systemic-sclerosis-with-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies